The Canada Health approval for Hyrimoz will be followed by a launch in February 2021, Sandoz Canada said.
The Sandoz adalimumab biosimilar Hyrimoz has been approved by Health Canada for the treatment of 9 rheumatologic and gastrointestinal conditions—in effect, all the indications as for the reference brand, Humira.
Adalimumab is a fully human tumor necrosis factor (TNF) blocker that helps to reduce inflammation. Health Canada granted marketing authorization for Hyrimoz in 3 subcutaneous injection dosage forms: 40 mg/0.8 mL and 20 mg/0.4mL in prefilled syringe, 40 mg/0.8 mL in autoinjector.
The indications include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
Sandoz Canada executive Karine Matteau said in a statement that the company intended to launch Hyrimoz by February 15, 2021, and said market potential is promising as 42,000 Canadian patients already receive treatment with adalimumab.
“We are currently working on the reimbursement of Hyrimoz to enable rapid access for patients.” said Matteau, vice president, Bio-Generic Hospital/Physician channel and Head Biosimilars at Sandoz Canada. “Sandoz is dedicated to growing our biosimilars portfolio in Canada and Hyrimoz is an important driver for this in the immunology area, as it complements the recent biosimilar launches we had this year in immunology and oncology.” In Canada, the company markets biosimilars for oncology, immunology, and endocrinology. These compete in a national market that has seen 32 biosimilar approvals to date, Sandoz Canada said.
Sandoz Canada said it would support the rollout with patient support that includes reimbursement navigation, financial assistance, administrative support, and a biosimilar education program for patients.
The regulatory approval for Hyrimoz marks the third approval for the company in Canada over the past 11 months. In August 2020, Sandoz Canada launched the pegfilgrastim and rituximab biosimilars Ziextenzo and Riximyo, respectively. Both agents were approved by Health Canada in April 2020.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.